Neurenati Therapeutics
Biotechnology Research
Hirschsprung disease (HSCR) is a deadly birth defect affecting 1/5000 children.
About us
Neurenati develops novel therapies for GI rare diseases
- Website
-
www.neurenati.com
External link for Neurenati Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2020
Employees at Neurenati Therapeutics
-
Maxime Ranger
PhD MBA | Startup company creator | Life sciences
-
Marielle Cohard-Radice
EVP Global Head of Development Operations, Daiichi Sankyo
-
Dana Matzen, PhD
Bio-Pharma C-Level Executive, Deal-Maker, Value Creation, Strategic Management, ex L.E.K. Consulting
-
Rodolphe Soret
Chercheur à l’UQAM | Université du Québec à Montréal